

Pursuant to the Colo. Rev. Stat. § 12-42.5-308 (2019), GlaxoSmithKline (GSK) makes the following pricing disclosure to individuals licensed by the State of Colorado to prescribe prescription drugs. The price(s) below represent the wholesale acquisition cost (or WAC) for SOTROVIMAB¹ as of the date of this notice.

WAC (also known as the list price) is the price to wholesalers and warehousing chains, not including prompt pay, stocking or distribution allowances, or other discounts, rebates or chargebacks. WAC may not represent prices charged to other customers, including specialty distributors, and is not the price that most patients pay for the product. For more information on the prices that patients pay, please check with the patient's healthcare provider.

Where available, GSK also identifies up to three (3) generic prescription drugs from the same therapeutic class as the GSK product listed. Please note that the identification of any generic product in the table below does not imply that that product is preferred, available commercially, interchangeable with any other product, nor is it intended to be a claim regarding the efficacy or safety of that product.

Prices are subject to change without notice. This notice is not a solicitation and does not constitute an offer to sell any GSK product.

WAC for SOTROVIMAB 500mg IV as of July 2021

<u>GSK Product Name w/ Strength</u>	<u>NDC or UPC</u>	<u>Pkg Size</u>	<u>WAC (Pkg)</u>	<u>Generic</u>	<u>Generic</u>	<u>Generic</u>
SOTROVIMAB 500mg IV	00173-0901-86	1 Vial	\$2,100.00	N/A	N/A	N/A

Prices appearing on this form were obtained from GSK data on file as of July 2021.

To access the full Prescribing Information for the GSK product, please visit us at
<https://gsksource.com/pharma/content/gsk/source/us/en/brands.html?type=Prescription>

¹ Trademarks are owned by or licensed to the GSK group of companies.